Cancer Cytogenetic Unit Lausanne University Hospital CHUV Lausanne Switzerland

Center of Oncocytogenetics Institute of Clinical Biochemistry and Laboratory Diagnostics General University Hospital and 1st Faculty of Medicine Charles University Prague Prague Czech Republic

Centre for Medical Genetics University Hospital Ghent Ghent Belgium

Cytogenetics Department St James's Hospital Leeds UK

Department of Biomedical Sciences University of Cagliari Cittadella Universitaria Monserrato Italy

Department of Clinical Genetics Our Lady's Children's Hospital Crumlin Dublin Ireland

Department of Genetics University of Groningen University Medical Centre Groningen RB Groningen The Netherlands

Department of Pathology Cancer Center Amsterdam VU University Medical Center MB Amsterdam The Netherlands

Génétique des tumeurs Laboratoire de Cytogénétique Pathologie Moléculaire Gustave Roussy Paris Villejuif France

Haematology Cellular and Molecular Diagnostic Service Great Ormond St Hospital London UK

Institute for Cancer Genetics and Informatics The Norwegian Radium Hospital Oslo University Hospital Oslo Norway

Laboratori de Citogenètica Molecular Servei de Patologia Hospital del Mar Barcelona Spain

Laboratory for Genetics of Malignant Disorders Department of Human Genetics University Hospital Gasthuisberg UZ Leuven Leuven Belgium

Northern Genetics Service Institute of Genomic Medicine Central Parkway Newcastle UK

Radboud University Nijmegen Medical Centre Department of Human Genetics HB Nijmegen The Netherlands

UO Anatomia Patologica Ospedale di Circolo Polo Universitario Varese Italy

Women's Centre John Radcliffe Hospital Oxford University Hospitals NHS Trust Oxford UK

Zobrazit více v PubMed

Heim S, Mitelman F (eds): Cancer Cytogenetics: Chromosomal and Molecular Genetic Aberrations of Tumor Cells, 3rd edn. New York: Wiley-Blackwell.

European Cytogenetic Guidelines: ECA Newsletter, January 2012. Available at: http://e-c-a.eu/files/downloads/E.C.A._General_Guidelines_Version%202.0.pdf last accessed 16 January 2015.

ISO 15189:2012 Medical laboratories—Requirements for quality and competence.

Claustres M, Kožich V, Dequeker E et alon behalf of the ESHG Quality committee: Recommendations for reporting results of diagnostic genetic testing (biochemical, cytogenetic and molecular genetic) (2013). Eur J Hum Genet 2013; 22: 160–170. PubMed PMC

Shaffer LG, McGowan-Jordan J, Schmid M: ISCN 2013: An International System for Human Cytogenetic Nomenclature. Basel: S Karger, 2013.

European co-operation for accreditation: Available at: http://www.european-accreditation.org/ last accessed 16 January 2015.

UK NEQAS Executive Office: Sheffield S10 2PB. Available at: http://www.ukneqas.org.uk/ last accessed 16 January 2015.

Krijgsman O, Israeli D, Haan JC et al: CGH arrays compared for DNA isolated from formalin-fixed, paraffin-embedded material. Genes Chromosomes Cancer 2012; 51: 344–352. PubMed

Sie D, Snijders PJ, Meijer GA et al: Performance of amplicon-based next generation DNA sequencing for diagnostic gene mutation profiling in oncopathology. Cell Oncol (Dordr) 2014; 37: 353–361. PubMed

Tuononen K, Mäki-Nevala S, Sarhadi VK et al: Comparison of targeted next-generation sequencing (NGS) and real-time PCR in the detection of EGFR, KRAS, and BRAF mutations on formalin-fixed, paraffin-embedded tumor material of non-small cell lung carcinoma-superiority of NGS. Genes Chromosomes Cancer 2013; 52: 503–511. PubMed

The Royal College of Pathologists:The Retention and Storage of Pathological Records and Archives. London: The Royal College of Pathologists, 2006.

Peiró G, D Mayr D, Hillemanns P et al: Analysis of HER-2/neu amplification in endometrial carcinoma by chromogenic in situ hybridization. Correlation with fluorescence in situ hybridization, HER-2/neu, p53 and Ki-67 protein expression, and outcome. Mod Pathol 2004; 17: 277–287. PubMed

Van Loo P, Nilsen G, Nordgard SH et al: Analyzing cancer samples with SNP arrays. Methods Mol Biol 2012; 802: 57–72. PubMed

Krijgsman O, Carvalho B, Meijer GA, Steenbergen RD, Ylstra B: Focal chromosomal copy number aberrations in cancer-Needles in a genome haystack. Biochim Biophys Acta 2014; 1843: 2698–2704. PubMed

Krijgsman O, Israeli D, van Essen HF et al: Detection limits of DNA copy number alterations in heterogeneous cell populations. Cell Oncol (Dordr) 2013; 36: 27–36. PubMed

McGranahan N, Swanton C: Biological and therapeutic impact of intratumor heterogeneity in cancer evolution. Cancer Cell 2015; 27: 15–26. PubMed

de Vree PJ, de Wit E, Yilmaz M et al: Targeted sequencing by proximity ligation for comprehensive variant detection and local haplotyping. Nat Biotechnol 2014; 32: 1019–1025. PubMed

Watson IR, Takahashi K, Futreal PA, Chin L: Emerging patterns of somatic mutations in cancer. Nat Rev Genet 2013; 14: 703–718. PubMed PMC

Scheinin I, Sie D, Bengtsson H et al: DNA copy number analysis of fresh and formalin-fixed specimens by shallow whole-genome sequencing with identification and exclusion of problematic regions in the genome assembly. Genome Res 2014; 24: 2022–2032. PubMed PMC

Ding L, Wendl MC, McMichael JF, Raphael BJ: Expanding the computational toolbox for mining cancer genomes. Nat Rev Genet 2014; 15: 556–570. PubMed PMC

Rigter T, Henneman L, Kristoffersson U et al: Reflecting on earlier experiences with unsolicited findings: points to consider for next-generation sequencing and informed consent in diagnostics. Hum Mutat 2013; 34: 1322–1328. PubMed PMC

Ulahannan D, Kovac MB, Mulholland PJ, Cazier J-B, Tomlinson I: Technical and implementation issues in using next-generation sequencing of cancers in clinical practice. Br J Cancer 2013; 109: 827–835. PubMed PMC

Tripathy D, Harnden K, Kimberly Blackwell K, Robson M: Next generation sequencing and tumor mutation profiling: are we ready for routine use in the oncology clinic? BMC Med 2014; 12: 140 http://www.biomedcentral.com/1741-7015/12/140/—ins1. PubMed PMC

Ambros PF, Ambros IM, Brodeur GM et al: International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee. Br J Cancer 2009; 100: 1471–1482. PubMed PMC

Walker RA, Bartlett JM, Dowsett M, Ellis IO et al: HER2 testing in the UK: further update to recommendations. J Clin Pathol 2008; 61: 818–824. PubMed

Wolff AC, Hammond MEH, Hicks DG et al: Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update. J Clin Oncol 2013; 31: 3997–4014. PubMed